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We tested the eﬀectofAstragalusmembranaceus(AM)onacutehemorrhagicstroke.Seventy-eightpatientswererandomlyassigned
to Group A (3 g of AM three times/day for 14 days); or Group B (3 g of placebo herb). A total of 68 patients (Group A 36, Group
B 32) completed the trial. The increase of functional independence measure scale score between baseline and week 4 was 24.53 ±
23.40, and between baseline and week 12 was 34.69 ± 28.89, in the Group A was greater than 11.97 ± 11.48 and 23.94 ± 14.8 in
the Group B (both P  0.05). The increase of Glasgow outcome scale score between baseline and week 12 was 0.75 ± 0.77 in the
Group A was greater than 0.41 ± 0.50 in the Group B (P<0.05). The results are preliminary and need a larger study to assess the
eﬃcacy of AM after stroke.
1.Introduction
Intracerebral hemorrhage (ICH) is a subtype of stroke with
high morbidity and mortality, accounting for approximately
15% of all deaths from stroke [1]. Many patients make only
a partial or poor recovery, and 36% of acute hemorrhagic
stroke patients remain moderately to severely disable at dis-
charge [2]. Therefore, treatments to enhance their recovery
are necessary. Clinical research performed in China based on
traditional Chinese medicine (TCM) may reveal new pos-
sibilities for the treatment of strokes. However, these treat-
mentshavelimitedacceptabilityoutsideChinabecauseofthe
Westernmedicalworld’sunfamiliaritywiththeTCMconcept
of stroke, which is relatively diﬀerent from the Western view.
Pharmacological studies have demonstrated that several
TCM herbs possess antioxidant, antiinﬂammatory, and anti-
glutamate properties [3]. Such herbs can dilate blood ves-
sels, suppress platelet aggregation, protect against ischemic
reperfusion injury, and enhance the tolerance of ischemic
tissue to hypoxia [4]. Astragalus membranaceus (AM) is a
traditional Chinese herb that has been used extensively in
China as a drug to facilitate recovery after a stroke. Clinical
studies performed in China have shown that AM enhances
stroke patients’ recovery from their neurological disability
and improves functional outcome [5, 6]. However, these
trials did not comply with the International Conference
on Harmonization and Good Clinical Practice guidelines,
and they used positive controls. Furthermore, the outcome2 Evidence-Based Complementary and Alternative Medicine
measures were not the standard scales used in modern stroke
trials. One study [5, 6] suggested that the eﬀectiveness of AM
in improving stroke recovery may be related to the herb’s
role in reducing the area of cerebral infarction area, and
its antioxidative qualities. Because no previous studies had
researched the use of AM with hemorrhagic stroke patients,
we investigated whether AM can enhance the functional
recovery of hemorrhagic stroke patients. Our study was
conducted in accordance with the International Conference
on Harmonization and Good Clinical Practice guidelines.
The objective of this research was to obtain pilot data to
support the design of a larger, controlled trial in the future.
Ganglionic (putamen, caudate, and thalamus) hemor-
rhagesarethemostcommonformsofICH,followedbylobar
hemorrhages, and then those of the cerebellum or pons [1].
Location is important for outcome (pontine hemorrhages
result in higher mortality), potential surgical intervention,
and underlying cause. To evaluate the eﬃcacy of AM, we
chose patients who had the same location of ICH, namely,
putaminal ICH, to minimize bias.
2.MaterialsandMethods
2.1. Subjects. Patients were recruited from China Medical
University Hospital’s neurosurgery and emergency depart-
ments between January 1, 2008 and December 21, 2010. All
patients were recruited within 24 hours after the onset of
hemorrhagic stroke. The experimental procedures complied
with the ethical principles dictated in the Declaration of
Helsinki, and the protocol of the trial was approved by
the institutional review board of China Medical University
Hospital, Taichung City, Taiwan (IRB: DMR 96-IRB-126).
The trial was conducted according to the International
Conference on Harmonization and Good Clinical Practice
guidelines. Patients gave their informed consent to partici-
pate.
The criteria for including patients in the study were as
follows: (1) female or male; (2) aged between 30 and 75
years; (3) randomized allocation to a study group within 24
hours of hemorrhagic stroke onset; (4) this was the patient’s
ﬁrst hemorrhagic stroke, and the location of hemorrhage
was the putamen; (5) treatment may or may not have been
included surgery; (6) the subject or their legal representative
gave written informed consent to participate. The exclusion
criteria were as follows: (1) recent thrombolysis treatment;
(2) history of previous stroke; (3) full-dose or long-term
anti-coagulation therapy; (4) hemorrhagic stroke but the
location was not putamen; (5) coexisting systemic diseases
such as terminal cancer, renal failure, liver cirrhosis, severe
dementia, or psychosis; (6) participation in another clinical
trial within the last three months; and (7) pregnancy or
lactation.
2.2. Preparation of AM. The AM was purchased from Shansi
Province, China. The origin of the herb was authenticated,
and the material was examined for microorganisms, heavy
metals, and pesticide according to the accepted standards
(good manufacturing practice or GMP) of Taiwan. The AM
was found to be of good quality, and the crude AM had been
extracted by Sun Ten Pharmaceutical Co. Ltd., Taiwan. The
AM was extracted at a rate of 3.0g from every 3.3g of crude
AM. The freeze-dried extracts of AM were veriﬁed by high-
performance liquid chromatography using Astragaloside IV
(Biotic Chemical Co. Ltd., China, Shanghai) as an active
component of AM. Finally, each 3g extract was sealed in an
aluminum foil sachet. The placebos were also made by Sum
Ten Pharmaceutical Co. Ltd. and were manufactured from
starch and sealed inside identical foil sachets.
2.3. Design and Sample Size. The present study was a single-
center, double-blind, placebo-controlled, randomized phase
II pilot study. The sample size was calculated according
to our hypothesis that AM can increase a patient’s score
on ten dimensions of the functional independence measure
Scale (FIM), and also on the Barthel Index (BI). We further
hypothesized that the increase in score would be evident
when comparing scores at baseline (the week of the stroke
onset) and week 4, and again at week 12. To achieve a
statistical power of 90%, the sample size would need to be
46 patients, and thus, 23 patients in each group. If the rate
of followup was 0.8, we would need to recruit 58 patients
(46 ÷0.8 = 58).
2.4. Randomization and Grouping. Random numbers were
generated by computer, using block randomization with a
b l o c ks i z eo f2o r4 .T h ep r e g e n e r a t e dr a n d o mn u m b e r sw e r e
placed in sealed envelopes, and a serial number was assigned
to each envelope according to the sequence of allocation of
the randomized number. Each envelope was then opened
sequentially, according to the admission sequence of subjects
at the study center. The number inside the envelope deter-
mined which group the subject was allocated to.
Subjects who were randomly assigned to Group A
received oral or nasopharyngeal administration of AM at
a rate of 3g three times per day for 14 days continuously
starting within 24 hours after stroke onset except standard
treatment that was according to Guidelines for the Man-
agement of spontaneous intracerebral hemorrhage in adults
(2007 update of American Stroke Association [7]). Patients
whowererandomlyassignedtoGroupBreceivedtheplacebo
treatment, according to exactly the same schedule as for
G r o u pA .S u b j e c t sa sw e l la si n v e s t i g a t o r sa n dp h a r m a c i s t s
were blinded to the patients’ allocation to each group. The
password for the randomization envelope for each subject
was known only by a designated researcher.
2.5. Outcome Measures. The primary outcome measures
were the diﬀerences in patients’ scores on several clinical
scales, between baseline (within 7 ± 1 days after the onset of
str ok e)andw eek4(28±4days),andbetweenatbaselineand
week 12 (84±10 days). The scales we used FIM, BI, Glasgow
Outcome Scale (GOS), and Modiﬁed Rankin Scale (MRS).
The scores of FIM, BI, GOS, and MRS were assessed by an
experienced research nurse.
T h es e c o n d a r yo u t c o m em e a s u r e sw e r ea sf o l l o w s :
(1) inﬂammatory index, which included the levels of C-
reactive protein (CRP) and erythrocyte sediment rateEvidence-Based Complementary and Alternative Medicine 3
Table 1: Demographic characteristics at baseline.
Group A Group B P-value∗
(n = 36) (n = 32)
Gender 0.74
Female 10 (27.78) 11 (34.38)
Male 26 (72.22) 21 (65.63)
Age (yrs) 56.08 ± 10.15 54.94 ±12.77 0.68
Age 0.78
<65 28 (77.78) 23 (71.88)
≥65 8 (22.22) 9 (28.13)
BT 36.85 ±0.71 37.36 ±3.58 0.43
Hematoma volume 27.94 ± 40.22 28.61 ±28.25 0.94
Craniotomy 1.00
No 25 (69.44) 22 (68.75)
Yes 11 (30.56) 10 (31.25)
Midline deviation 1.00
No 30 (85.71) 28 (87.50)
Yes 5 (14.29) 4 (12.50)
GPT 30.70 ± 22.59 35.39 ±32.19 0.57
GOT 48.54 ± 70.97 35.68 ±20.16 0.40
BUN 12.72 ±4.20 15.47 ±11.60 0.21
Creatinine 2.26 ± 8.19 0.95 ±0.50 0.34
PT 11.11 ±0.65 11.20 ±0.71 0.57
PTT 29.63 ±2.73 30.00 ±3.50 0.62
Hb 14.31 ±2.01 15.04 ±1.45 0.10
Plt 210.78 ±55.04 216.00 ±49.90 0.68
Hypertension 0.23
No 15 (41.67) 8 (25.00)
Yes 21 (58.33) 24 (75.00)
Hyperlipidemia 0.47
No 36 (100.00) 31 (96.88)
Yes 0 (0.00) 1 (3.13)
Hyperuricemia 1.00
No 35 (97.22) 32 (100.00)
Yes 1 (2.78) 0 (0.00)
DM 0.14
No 34 (94.44) 26 (81.25)
Yes 2 (5.56) 6 (18.75)
ICU 0.46
No 3 (8.33) 5 (15.63)
Yes 33 (91.67) 27 (84.38)
Angina 0.47
No 36 (100.00) 31 (96.88)
Yes 0 (0.00) 1 (3.13)
Anemia 1.00
No 35 (97.22) 31 (96.88)
Yes 1 (2.78) 1 (3.13)
DU bleeding 1.00
No 35 (97.22) 32 (100.00)
Yes 1 (2.78) 0 (0.00)
COPD 0.47
No 36 (100.00) 31 (96.88)
Yes 0 (0.00) 1 (3.13)4 Evidence-Based Complementary and Alternative Medicine
Table 1: Continued.
Group A Group B P-value∗
(n = 36) (n = 32)
Arrhythmia —
No 36 (100.00) 32 (100.00)
Yes 0 (0.00) 0 (0.00)
RCC 1.00
No 35 (97.22) 32 (100.00)
Yes 1 (2.78) 0 (0.00)
TB 1.00
No 35 (97.22) 32 (100.00)
Yes 1 (2.78) 0 (0.00)
Hypercholesterolemia 0.47
No 36 (100.00) 31 (96.88)
Yes 0 (0.00) 1 (3.13)
() represent %; Group A: complementary therapy with Astragalus membranaceus; Group B: complementary therapy with placebo; BT: body temperature;
craniotomy: craniotomy treatment with craniotomy; midline deviation: midline of brain deviated to right hemisphere or left hemisphere; GPT: glutamic
pyruvic transaminase; GOT: glutamic oxaloacetic transaminase; BUN: blood urea nitrogen; PT: prothrombin time; PTT: partial thromboplastin; Hb:
hemoglobin; Plt: platelets; DM: diabetes mellitus; ICU: intensive care unit; Angina: angina pectoris; DU bleeding: duodenal ulcer bleeding; COPD: chronic
obstructive pulmonary disease: RCC: coronary care unit; TB: pulmonary tuberculosis. ∗t-test for independent groups was used for used the continuous data;
chi-square test or ﬁsher’s exact test for categorical data.
(ESR)forvenousblood;theseweremeasuredatbase-
line (prior to the ﬁrst AM dose), and again on the
fourth and seventh day of admission;
(2) computer tomography (CT) examination, which was
done at baseline and on the fourth and seventh
days of admission. The volume of hematoma was
calculated the simpliﬁed equation 1/2 A × B × C,
where A is the maximum width measured, B is
the length, and C is the height [8]. The ratio of
brain edema was calculated by CT (volume of edema
divided by blood clot volume).
2.6. Statistical Analysis. Baseline variables were compared
using a two-group t-test for continuous variables (e.g., age)
and chi-squared (χ2) test for categorical variables (e.g.,
gender). Intention-to-treat analysis was used. For eﬃcacy
variables, comparisons were made between the two groups
at baseline and weeks 4 and 12, respectively. The two-
sample t-test was used separately for each comparison. To
allow for the possibility of nonnormal distribution, the non-
parametric Mann-Whitney test was performed. All analyses
were performed using SAS version 9.2 (SAS Institute Inc.,
Cary, NC). A P-value of  0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Baseline Characteristics of Demographic Data. Eighty
subjectswererecruitedinthisstudy,butonepatientwasover
the age of 75 and another patient declined to participate,
leaving a total of 78 patients randomized to assign either the
Group A or the Group B.
A total of 68 patients completed the trial, 36 patients in
Group A and 32 patients in Group B. The baseline charac-
teristics of Group A and Group B patients regarding gender,
age, body temperature (BT), craniotomy, and so forth were
summarizedinTable 1.ThreepatientsdroppedoutofGroup
A (one was older than 75, one withdrew, one died); and
seven patients dropped out of Group B (one withdrew,
one attended another program, one suﬀered deep vein
thrombosis, one left Taichung, and three died) see Figure 1.
3.2. Primary Outcome Measures. The FIM scale score at
baseline was similar in the two groups, namely, 62.42±40.32
for Group A and 56.97 ± 35.82 for Group B (P>0.05;
Figure 2). The increase of FIM scale score between baseline
a n dw e e k4w a s2 4 .53 ± 23.40, and between baseline and
week 12, it was 34.69 ± 28.89 : in the Group A was greater
than 11.97 ± 11.48 and 23.94 ± 14.8 in the Group B (both
P  0.05; Figure 2).
No statistically signiﬁcant diﬀerence was found between
the two groups’ FIM subscales scores, at baseline, for the fol-
lowing subscales: eating, dressing upper body, bladder man-
agement, bowel management, transfers (bed/chair/wheel-
chair), transfers (toilet), transfers (bathtub/shower), trans-
fers (walking/wheelchair) and locomotion (stairs), all P>
0.05; Figure 3.
FIMsubscalescoresatbaseline,andbetweenbaselineand
week 12 were similar between Group A and Group B (all
P>0.05; Figure 3), whereasGroup A achieved a signiﬁcantly
greater diﬀerence than Group B between baseline and week
4 for the subscales: comprehension (P<0.05), expression
(P<0.05), social interaction (P  0.01), problem solving
(P<0.05), and memory (P<0.05) (Figure 3).
The ﬁndings shown in Figure 3 indicate that Group A
achieved signiﬁcantly greater score changes than did Group
B in several FIM domains. Group A achieved a signiﬁcantly
greater diﬀerence than Group B for the subscale “grooming,”
between baseline and week 4 (P  0.01), and between
baseline and week 12 (P<0.05). Group A also achievedEvidence-Based Complementary and Alternative Medicine 5
t.i.d./day for 14 days continuously), starting
within 24 hours after stroke onset
80 acute hemorrhagic stroke patients were
recruited
Two patients were excluded:
78 patients randomized
Completed trial (n = 68)
Group A 36 patients; Group B 32 patients
Seven patients dropped out:
Chinese herb Astragalus membranaceus (3 g with placebo (3 g t.i.d./day for 14
days continuously), starting within
24 hours after stroke onset
one withdrew after signing informed consent
Group B: complementary therapy Group A: complementary therapy with
(1) check CRP and ESR,
(2) calculate BER 
(1) check CRP and ESR,
(2) calculate BER
At weeks 1, 4, and 12 after admission assess: At weeks 1, 4, and 12 of admission assess:
(2) Barthel index scale score,
(3) Glascow outcome scale score,
(2) Barthel index scale score,
(3) Glascow outcome scale score,
(1) functional independence measure scale score, (1) functional independence measure scale score,
three died,
one withdrew,
one suered deep vein thrombosis,
one participated in another trial,
one left Taichung
Statistic analysis
(4) modiﬁed Rankin scale score (4) modiﬁed Rankin scale score
one was older than 75 years,
On 1st, 4th, and 7th day of admission: On 1st, 4th, and 7th day of admission:
Three patients dropped out:
one died,
one was older than 75 years,
one withdrew
Figure 1: Flowchart.
a signiﬁcantly greater diﬀerence than Group B for the sub-
scale“bathing/showering,” betweenbaselineandweek4(P<
0.05), and between baseline and week 12 (P<0.05). Group
A score changes for the subscale “dressing lower body” were
also signiﬁcantly higher than those of Group B at both time
intervals (baseline to week 4, P = 0.05); baseline to week
12 (P<0.05). Group A score changes for the subscale
“toileting” were signiﬁcantly higher than those of Group B at
both time intervals (baseline to week 4, P  0.01; baseline to
week 12, P<0.05). The score diﬀerences for other subscales
are summarized in Figure 3.
As shown in Figure 2, the two groups had similar BI
scores at baseline (39.86 ± 38.87 in Group A, and 30.94 ±
33.92 in Group B; P>0.05). There was also no statistically6 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Eﬀect of Astragalus membranaceus on primary outcome measures in acute hemorrhagic stroke patients. The increase of FIM scale
scoresinthegroupAwasgreaterthaninthegroupBinweek4andinweek12inacutehemorrhagicstrokepatients.GroupA:complementary
therapy with Astragalus membranaceus; Group B: complementary therapy with placebo; FIM: functional independence measure; BI: Barthel
index; GOS: Glasgow outcome scale; MRS: Modiﬁed Rankin scale; B: baseline (week 1); W4: week 4; W12: week 12; (a) P = 0.05; (b)
P<0.05; (c) P  0.01 compared to the increase of Group B.
signiﬁcant diﬀerence between Group A and B changes in
scores from baseline to week 4, or from baseline to week 12
(both P>0.05).
The GOS score at baseline was 3.25 ± 0.91 for Group A,
and 3.13 ± 0.83 for Group B, with the diﬀerence between
the groups not being signiﬁcant (P>0.05; Figure 2). The
diﬀerence in GOS scores between baseline and week 4 was
0.47 ±0.61 for Group A, and 0.25 ±0.44 for Group B, which
was not signiﬁcant (P>0.05; Figure 2). The diﬀerence in
GOS score between baseline and week 12 was 0.75 ±0.77 for
Group A, and 0.41 ± 0.50 for Group B, with the diﬀerence
between the groups being signiﬁcant (P<0.05; Figure 2).
The MRS score at baseline was 3.69 ± 1.51 for Group A,
and 4.06 ± 1.16 for Group B, with the diﬀerence between
groups not being signiﬁcant (P>0.05; Figure 2). For Group
A, the diﬀerence in MRS score between baseline and week 4
was −0.83 ± 0.94, and between baseline and week 12 it was
−1.50 ± 1.23. These results were not signiﬁcantly diﬀerent
from those of Group B, namely, −0.56 ± 0.80 and −1.09 ±
1.96, respectively, both P>0.05; Figure 2.
3.3. Secondary Outcome Measure. As shown in Figure 4, the
level of CRP on day 1 was 2.80 ± 4.71 for Group A, which
was not signiﬁcantly diﬀerent from the results for Group B,
namely, 2.69 ± 3.44 (P>0.05). For Group A, the change in
CRPbetweendays1and4was1.82±4.44,andbetweendays1
and 7 it was −0.13±3.98. These results were not signiﬁcantly
diﬀerent from those of Group B, namely, 2.90 ± 4.24 and
1.08 ± 6.87, respectively (both P>0.05) for the intergroup
diﬀerences at the two time periods, respectively.Evidence-Based Complementary and Alternative Medicine 7
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Figure 3: Eﬀect of Astragalus membranaceus on sub-scale of FIM scores in acute hemorrhagic stroke patients. The increase of FIM subscale
scores in grooming, bathing/showing, dressing lower body and toileting was greater in the group A than in the group B in week 4 and in
week 12 in acute hemorrhagic stroke patients. Group A: complementary therapy with Astragalus membranaceus; Group B: complementary
therapy with placebo; B: baseline (week 1); W4: week 4; W12: week 12; (a) P = 0.05; (b) P<0.05; (c) P  0.01 compared to the increase of
Group B.
The level of ESR on day 1 was 16.28±17.11 for Group A,
similarto15.72±18.11forGroupB(P>0.05;Figure 4).The
change in ESR for Group A was 23.28±21.30 between days 1
and 4, and 24.06 ±21.24 between days 1 and 7. These results
were similar to those of Group B, namely, 25.88 ± 27.47 and
31.78 ±28.27, respectively (both P>0.05; Figure 4).
T h el e v e lo fB E Ro nd a y1w a s2 .61 ± 0.92 for Group A,
similar to 2.72 ± 1.68 for Group B (P>0.05; Figure 4). The
change in BER for Group A was 3.70 ± 11.93 between days
1a n d4 ,a n d3 .73 ± 8.41 between days 1 and 7. These results
were similar to those of Group B, namely, 1.39 ± 2.82 and
1.76 ±2.34, respectively (both P>0.05; Figure 4).
3.4. Adverse Eﬀects. A total of 13 severe adverse events (SAE)
occurred in 10 patients (5 events in 4 patients of Group A; 8
events and 6 patients in Group B). The SAEs included pro-
longed admission (1 patient), second operation (2 patients),
respiratory failure (1 patient), pneumonia (1 patient),
ventriculoperitoneal shunt operation (1 patient), uterine
myoma (1 patient), urinary tract infection (1 patient), deep
venous thrombosis (1 patient), and four patients’ deaths (1
patient in Group A, and 3 in Group B). More minor adverse
events such as dizziness (13 patients), skin rash (2 patients),
and fever (22 patients) were also noted. The SAEs were
considered not to be related to the medication under study.
The deaths were considered to be due to rebleeding of the
intracerebralhematoma,whichcausedincreasedintracranial
pressure; this was not related to the study medications.
4. Discussion
Our results indicated that the FIM and GOS scores of Group
A (patients treated with complementary therapy AM) were
similar to those of Group B (placebo) at baseline. The
increase in FIM scores was greater for Group A at week 4
and again at week 12, relative to Group B. The increase in
GOS scores was greater for Group A than Group B at week
12. The score changes for BI and MRS were not signiﬁcantly
diﬀe r e n ta tw e e k4a n da tw e e k1 2c o m p a r e dt ot h eﬁ r s tw e e k
after stroke onset.
Therefore, we suggest that AM provides an advantage
for acute hemorrhagic stroke patients, if treatment with AMEvidence-Based Complementary and Alternative Medicine 9
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Figure 4: Eﬀect of Astragalus membranaceus on secondary outcome measures in acute hemorrhagic stroke patients. The increase of C-
reactive protein (CRP) levels and erythrocyte sediment rate (ESR), and brain edema ratio in the group A was similar to in the group B
in day 4 and in day 7 in acute hemorrhagic stroke patients. Group A: complementary therapy with Astragalus membranaceus;G r o u pB :
complementary therapy with placebo; D1: baseline, prior to administration of Astragalus membranaceus; D4: fourth day of admission; D7:
seventh day of admission.
is started within 24 hours of stroke onset. In particular,
we found that AM therapy enhanced patients’ functional
recovery for grooming, bathing, showering, dressing the
lower body, and toileting. Additionally, the results show an
excellent safety proﬁle for treatment with AM; overall, the
treatment was well-tolerated and none of the observed SAEs
were considered drug related.
The pathological changes because of brain injury after
ICH include hematoma expansion, midline shift, and brain
edema. Enlargement of the hematoma after ictus contributes
to midline shift and accelerates neurological deterioration
[9–11]. Perihematomal brain edema develops immediately
afteranICHandpeaksseveraldayslater[12,13].Inhumans,
perihematomaledemadevelopswithin3hofsymptomonset
and peaks between 10 and 20 days after ictus [14, 15].
The formation of edema after ICH increases intracranial
pressure and can result in herniation [16, 17]. Several studies
have shown that the degree of brain edema around the
hematoma is associated with outcome, with worse edema
being associated with poorer outcomes [11, 18]. There are
several phases of edema formation after ICH. The early
phase (ﬁrst few hours) involves hydrostatic pressure and
clot retraction, with movement of serum from the clot into
the surrounding tissue [19]. The second phase (ﬁrst two
days) is related to the coagulation cascade and thrombin
production; and the third phase is related to erythrocyte10 Evidence-Based Complementary and Alternative Medicine
lyses and haemoglobin toxicity. Therefore, the mechanism of
edema includes hematoma, oxidation, and inﬂammation.
Therapy with AM has the eﬀect of antioxidation and
anti-inﬂammation, which indicates that AM can decrease
edema and improve the patient’s prognosis [20, 21]. Our
results showed that AM therapy improved functional out-
c o m e sa tw e e k4a n da tw e e k1 2a f t e rh e m o rr h a gi cs t r o k eo n -
set, which may be due to AM’s properties of anti-inﬂamma-
tion and antioxidation, which would decrease brain edema.
A growing body of evidence suggests that inﬂammation
after both ischemic stroke and ICH or higher brain edema is
predominantlydeleterious.Inhumanstroke,prestrokeinfec-
tion is associated with worse outcome, as recently reported
in a review by McColl and colleagues [22]. High levels of
CRP, which is an acute-phase protein released by the liver
in response to IL-6, are linked to worse outcome following
stroke [23], and acute prestroke administration of human
CRP is deleterious in experimental models [24]. It may be
that CRP enhances complement-mediated neutrophil chem-
otaxis and degranulation. Inﬂammation aggravates hemor-
rhagic brain injury. An inﬂammatory response in the sur-
rounding brain occurs soon after ICH and peaks several days
later in human beings and in animals [25, 26]. In addition to
CRP, another indicator of inﬂammation is ESR.
Our results leave one question unanswered. That is, why
did FIM scores increase more for Group A than Group B
at weeks 4 and 12, and GOS scores also increased more
in Group A at week 12 relative to Group B, whereas the
groups did not show any signiﬁcant diﬀerences regarding
changes in CRP, ESR, and BER? In response to this question,
we suggest that the eﬀect of AM eﬀect gradually increases,
with the greatest eﬀect occurring after seven days. Our study
design was such that we stopped measuring CRP and ESR
and performing CT scans after the seventh day; we measured
on days 1, 4, and 7 after admission. This possible explanation
requires further study.
One study, which reviewed data from 586 patients with
I C Hs e e na t3 0d i ﬀerent medical centers, reported that
hemorrhagic stroke mortality at 3 months was 34% [27].
Ganglionic (putamen, caudate, and thalamus) hemorrhages
are the most common forms of ICH, followed by lobar, and
then cerebellar or pontine [1]. Location is important for
outcome (pontine hemorrhages result in higher mortality),
potential surgical intervention, and underlying cause. Our
results indicated that the mortality of putaminal ICH is
approximately 5 to 6%, which is lower than for average
ICH. Therefore, putaminal ICH is associated with a better
outcome than other locations of ICH.
Our study was subject to some limitations. The sample
size of 68 subjects was insuﬃcient to draw any ﬁrm con-
clusions on the eﬃcacy of the treatment. The study itself
was an exploratory analysis, with the objective of generating
hypotheses for future, larger trials. In addition, our data
analysis did not consider the inﬂation of type I error due
to multiple comparisons. All observed results were not
statistically signiﬁcant if Bonferroni correction for multiple
comparisons was made. Although testing multiple response
variables with Bonferroni correction is technically correct,
it is seldom used by most of clinical trials in the literature.
However, trends were observed, and our results provided
some estimates for sample sizes, which would be required to
achieve statistical signiﬁcance in future studies. The duration
of the treatment and of the study itself was shorter than that
of other trials assessing the eﬃcacy of AM after stroke. This
suggests that a longer trial period could also be an important
criterion for subsequent protocols.
In conclusion, the ﬁndings of our study are preliminary,
and a larger study to assess the eﬃcacy of AM after stroke is
needed.
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